Ex-BioNTech Execs Launch 'AI-Native' Cancer Surveillance Company Bios Life with $25M and Tempus Partnership
核心洞察
Bios Life (搜索), an "AI-native cancer (搜索) surveillance company" founded by former BioNTech executives, launched from stealth with $25 million in seed funding led by Redmile (搜索), Vsquared Ventures (搜索), and Kindred Capital (搜索).
The company targets over 40 million high-risk individuals and cancer (搜索) survivors in the US who face fragmented, reactive care, aiming to deliver personalized risk assessment, tailored screening, and survivorship care.
A strategic alliance with AI specialist Tempus (搜索) provides access to more than 7 million de-identified patient records to train and validate predictive models across common cancers.
Two senior executives formerly at mRNA specialist BioNTech have launched a new biotech called Bios Life (搜索), which they describe as "an AI-native cancer (搜索) surveillance company." Ex-BioNTech chief strategy officer Ryan Richardson serves as chief executive, while Zach Taylor, formerly a senior vice president at BioNTech, takes on the role of chief operating officer. The company debuts with $25 million in seed financing led by Redmile (搜索), Vsquared Ventures (搜索) and Kindred Capital (搜索), with additional support from a collective of prominent healthcare and technology investors across the US and Europe.
Bios Life (搜索) intends to develop a virtual clinic offering a personalised and continuous approach to cancer (搜索) screening and care, including for cancer survivors and high-risk individuals, in what it calls a "new category of cancer care." According to Richardson, people who survive a cancer diagnosis or who are at high risk of developing the disease — around 40 million people in the US — often fall through the cracks of current healthcare systems and face fragmented and reactive care.
A Critical Unmet Need
The company is addressing a substantial clinical gap. In the US alone, over 40 million people are either at increased risk for cancer (搜索) or are cancer survivors. With more than 40% of individuals projected to be diagnosed with cancer during their lifetime, and over 30% of those cases identified at stages 3 or 4, Bios Life (搜索) is targeting a critical need with its predictive care platform.
Kevin Oeffinger, MD, Director of the Duke Cancer (搜索) Institute Center for Onco-Primary Care, underscored the stagnation in the field: "Cancer screening and surveillance have been at a relative standstill for the past 20-30 years. The vast majority of individuals at elevated risk of cancer are not screened according to standard-of-care guidelines, and one out of every five newly diagnosed cancers in the US is found in cancer survivors."
Technology Platform and Tempus Alliance
Bios Life (搜索) — which has teams in place in the US and UK — aims to deliver personalised risk assessment, tailored screening, and survivorship care with the goal of "finding cancer (搜索) sooner, intervening smarter, and improving lifelong outcomes at scale."
The company starts operations with the help of a strategic alliance with AI specialist Tempus (搜索), which was set up around a massive database of more than 7 million de-identified patient records — including imaging data, genomic information, transcriptomics profiles, and clinical text — that will be used to train, validate, and deploy predictive models across a wide range of common cancers.
The core of Bios Life (搜索)'s platform comprises proprietary technologies, including its Personalized Cancer (搜索) Risk and Cancer Surveillance Platforms. The company has also secured commercial rights to the Nucleotide Transformer genomics foundation model from BioNTech-InstaDeep, recognized as one of the most cited AI genomics models globally, capable of analyzing genomic signals at a single-nucleotide level.
The company's advanced AI technology platforms enable the delivery of tailored cancer (搜索) surveillance and holistic supportive care for each individual's unique circumstances. This results in the creation of a digital twin for every patient, which continuously updates their biological model, shifting from isolated screening episodes to integrated lifetime surveillance.
Furthermore, in collaboration with Ambry Genetics (搜索), now part of Tempus (搜索), Bios Life (搜索) plans to incorporate genetic screening into its preventive platform along with physician-ordered genetic testing within its survivorship program.
Leadership and Clinical Vision
"Tens of millions of high-risk individuals and cancer (搜索) survivors lack access to cutting-edge care which is tailored to their particular needs and their unique biology," said Richardson. "Bios Life (搜索) is building a novel technology portfolio and specialised care delivery model to uniquely serve these individuals at a level that has not been possible until now — one that is deeply personalised and delivered at scale."
Ryan Fukushima, CEO of Data and Apps at Tempus (搜索), added: "At Tempus, we believe the future of cancer (搜索) care isn't just better treatments, it needs better prediction. Our collaboration with Bios Life (搜索) is an opportunity to rethink how we identify, monitor and support individuals at elevated risk for cancer over the course of their lives."
Bios Life (搜索)'s leadership team includes Co-founder and Chief Operating & Business Officer Zach Taylor, and Co-founder and Chief Medical Officer Logan Frank, MD, a board-certified radiologist. The team also includes technology experts such as Geoff Hyde, Head of Product and Engineering, and Thomas Pierrot, PhD, Head of Artificial Intelligence.
Launch Plans
The company hopes to deliver its virtual clinic model in partnership with oncology centres around the US, giving it access to care teams. Bios Life (搜索) plans to launch its platform in the US in the latter half of 2026, and consumers can currently join the waitlist at www.bioslife.ai.
Oeffinger concluded that the AI-enhanced virtual model "has the potential to greatly enhance the delivery of care to these high-risk populations; this is a game changer. Utilizing AI tools with a genetic and lifestyle backbone will move us from stagnation to the long-promised potential of personalized and precise cancer (搜索) screening."